Arab Board Dermatology Clinical common mistakes
Arab Board Dermatology Clinical · Understand the traps and how to avoid them.
Committing to a single diagnosis and stopping the differential before deliberately listing the 'must-not-miss' alternatives for the morphologic pattern (e.g., calling every annular scaly plaque tinea without considering nummular eczema, pityriasis rosea, or mycosis fungoides).
Exam stems are written to reward pattern recognition speed, so candidates anchor on the first familiar gestalt and spend remaining time confirming rather than excluding; the clinical reasoning step is never verbalized.
What to do instead
After forming a leading diagnosis, force a 30-second written 'rule-out list' of 2–3 dangerous or treatable mimics keyed to the morphology and time course, and check each against the stem's negatives before answering.
Treating 'biopsy' as a last resort and selecting a descriptive label instead of the diagnosis-defining test when the stem gives chronicity, treatment failure, or atypical features.
Trainees are conditioned to answer with the most likely clinical diagnosis, and biopsy feels like 'giving up'; they also fear choosing an invasive option when a benign one exists.
What to do instead
Memorize trigger phrases that mandate tissue sampling (atypical morphology, failure of appropriate therapy, ulceration, new lesion in an adult, systemic symptoms) and default to biopsy when any are present.
Managing chronic plaque psoriasis with topical therapy alone in a stem describing >10% BSA, joint symptoms, or repeated flares, rather than escalating to phototherapy or systemic/biologic therapy.
Candidates focus on the correct topical agent and miss the severity-stratification step, and they under-weight extracutaneous clues like nail pitting and dactylitis as signals for systemic disease.
What to do instead
Before answering any psoriasis item, explicitly grade severity (BSA, PASI, special sites, joints, quality of life) and let that grade drive the therapeutic tier; treat nail and joint findings as automatic escalation triggers.
Diagnosing 'eczema' in an adult with new-onset flexural or hand dermatitis without taking an occupational exposure and patch-test history, missing allergic contact dermatitis.
Atopic dermatitis is over-represented in training, and the stem's itch and lichenification fit the template, so the exposure history is skimmed.
What to do instead
For any adult-onset or treatment-refractory dermatitis, ask three questions in order: distribution matching an external contactant, temporal relation to a new product or job, and prior patch testing; select patch testing over another steroid potency increase.
Prescribing isotretinoin or a new systemic agent without first confirming pregnancy status and contraception plan, or continuing tetracycline-class antibiotics in a pregnant patient with acne.
The dermatologic severity dominates the vignette and the reproductive-safety step feels like administrative detail rather than the tested decision point.
What to do instead
Adopt a fixed prescribing checklist for every acne/rosacea item: pregnancy test, two contraception methods, iPLEDGE-type monitoring, and drug-specific teratogenicity; answer the safety question before the efficacy question.
Labeling every flushing, papulopustular, or steroid-worsened facial eruption as rosacea, missing steroid-induced rosacea, seborrheic dermatitis, demodicosis, or lupus.
Rosacea is a frequent correct answer and its triggers overlap with many mimics; candidates do not systematically check for a history of topical steroid use or photosensitivity.
What to do instead
For facial erythema items, run a four-item discriminator: steroid history, photosensitivity/scarring, distribution (nasolabial vs malar vs perioral), and presence of comedones or Demodex scale; only then commit.
Choosing topical antifungal monotherapy for a stem showing kerion, widespread tinea corporis, or onychomycosis with nail matrix involvement, and missing the need for systemic therapy or the risk of steroid-modified tinea.
Tinea is taught as a 'topical disease' and the severity cues (boggy plaque, pustules, hair loss, extensive surface area) are not connected to route of therapy.
What to do instead
For every fungal item, classify by site and depth (stratum corneum vs hair follicle vs nail matrix) and by extent; hair-follicle and matrix involvement mandate oral therapy, and prior topical steroid use should raise suspicion of tinea incognito.
Interpreting a positive ANA as diagnostic of lupus and answering accordingly, instead of weighting specific antibodies, clinical criteria, and pretest probability.
The ANA is the most familiar lupus test, and stems often include it as a distractor; candidates conflate screening sensitivity with diagnostic specificity.
What to do instead
For connective tissue disease items, require a specific antibody (dsDNA, Sm, Ro/La, U1RNP, Jo-1, centromere, Scl-70) plus a compatible clinical criterion before selecting a diagnosis, and treat isolated low-titer ANA as nondiagnostic.
Withdrawing systemic corticosteroids abruptly or failing to taper in a patient with suspected pemphigus vulgaris or bullous pemphigoid, and choosing the wrong confirmatory test (e.g., ordering only H&E when direct immunofluorescence is decisive).
Acute control of blistering feels like the priority, and the immunofluorescence/perilesional biopsy logistics are less familiar than histology.
What to do instead
For blistering items, always pair the diagnosis with the correct sampling (perilesional skin for DIF, fresh vesicle for H&E) and specify a slow taper plus steroid-sparing agent; check mucosal involvement to separate pemphigus from pemphigoid.
Missing Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with fever, mucosal erosions, and a drug started 1–3 weeks earlier, and instead treating for infection or staphylococcal scalded skin syndrome without checking Nikolsky sign and detachment percentage.
Early SJS/TEN looks nonspecific, and the timeline and mucosal triad are easy to under-read under time pressure.
What to do instead
For any febrile eruption with mucosal involvement, calculate body surface area of detachment, test Nikolsky, and review the drug timeline; classify SJS vs TEN by detachment percentage and prioritize withdrawal of the culprit drug and burn-unit-level supportive care.